(Q50559457)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Gender influence on treatment of chronic hepatitis C genotype 1 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

Janaína L Narciso-Schiavon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

Leonardo de Lucca Schiavon

5 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Roberto José Carvalho-Filho

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Juliana Peghini Sampaio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Philipe Nicolas El Batah

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Denize Vieira Barbosa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Maria Lucia Gomes Ferraz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Antonio Eduardo Benedito Silva

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

1 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

Revista da Sociedade Brasileira de Medicina Tropical

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

217-223

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Anti-hepatitis C virus-positive blood donors: are women any different?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Natural histories of hepatitis C virus infection in men and women simulated by the Markov model

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Hepatitis C virus clearance is prominent in women in an endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Higher clearance of hepatitis C virus infection in females compared with males

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Clearance and persistence of hepatitis C virus in a Tunisian population: association with HLA class I and class II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Classification of chronic viral hepatitis: a need for reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naïve, relapser and non-responder patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis c patients treated with peginterferon-alpha2b and ribavirin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Alcohol use and treatment of hepatitis C virus: results of a national multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Standardization of hepatitis C virus RNA quantification

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0037-86822010000300001

10.1590/S0037-86822010000300001

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563484%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference